Below 200 billion!

From the perspective of the bid-winning enterprises (groups), Kelun Pharmaceutical won the bid for 11 products in total, becoming the vanguard of the centralized procurement of systemic anti-infective drugs
.
Up to now, there are more than 100 products that have been reviewed/deemed to have been reviewed for systemic anti-infective drugs, and Kelun involves 21 products.
It is expected to continue to play a leading role in the subsequent new collections
.

5 Class 1 new drugs are gearing up, and 20 first imitations are ready to go

Among the new systemic anti-infective drugs declared for marketing since 2018 (excluding vaccines, immune serum and immunoglobulin), there are currently 12 under review and approval, involving 5 Class 1 new drugs
.

The compound ACC007 tablet of Aidi Pharmaceuticals is a class 1 new drug in the field of anti-AIDS.
The company combines two nucleoside reverse transcriptase inhibitors (lamivudine and tenofovir) on the basis of ACC007 (ainovirin tablets).
) The first domestically developed three-in-one single-tablet compound innovative drug preparation
.
It is reported that its combination plan and drug selection are in line with international trends, and in December 2019, it was included in the national 13th Five-Year "Major New Drug Creation" major science and technology project
.
The patient only needs to take 1 tablet a day, no need to take other anti-AIDS drugs, which helps to reduce the burden of taking medication, increase compliance, and reduce the occurrence of drug resistance
.

Helebuvir tablets and recombinant human-derived anti-rabies monoclonal antibody injections that are included in the priority review on the grounds of "clinically needed shortage drugs, innovative drugs and improved new drugs for the prevention and treatment of major infectious diseases and rare diseases" Antiviral drugs for systemic use
.
Helebuvir Tablets is a new class 1 anti-HCV (chronic hepatitis C) drug and the first domestically developed NS5B inhibitor with strong liver targeting ability and high antiviral activity
.
Recombinant human-derived anti-rabies virus monoclonal antibody injection is an independent innovation project of North China Pharmaceutical, and is listed as a major scientific and technological special product of the country’s "Major New Drug Creation".
Its mechanism and indications are combined with human rabies vaccines to supplement humans.
The antibody blank during the active immunization process with rabies vaccine can directly neutralize the rabies virus in the body and play a passive immune effect.
It is used for passive immunization of patients who are bitten or scratched by rabies or other rabies virus-susceptible animals
.

ZL-2401 p-toluenesulfonate tablets and ZL-2401 p-toluenesulfonate for injection that were included in the priority review on the grounds of "innovative drugs with obvious therapeutic advantages" are from Zai Lab
.
ZL-2401 p-toluenesulfonate is a new type of tetracycline, which is designed to overcome tetracycline resistance and has broad-spectrum antibacterial activity, including gram-positive bacteria, gram-negative bacteria, atypical pathogens and a variety of resistant strains The indications for delivery are community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI)
.

The first class of new drugs blasted the eye, and the first imitation of the heavyweights should not be underestimated
.
Among the generic drugs that have been declared for listing and are under review since 2018, 20 are expected to become the first domestic imitations
.

The competition for the first imitation of Oseltamivir Phosphate Dry Suspension is the fiercest, involving 8 companies.
Dongyang Pharmaceutical, the leading company of Oseltamivir, has also participated in the competition.
Who will win the competition? We are waiting for the result
.
In addition, the dispute over the first imitation of emtricitabine propofol tenofovir fell on Qilu and Beite.
Gilead’s original product will have global sales of more than $1.
8 billion in 2020
.
Tedizolamide phosphate for super antibiotic injection was approved for import in 2019.
At present, Nanjing Zhengda Tianqing Pharmaceutical, Ruiyang Pharmaceutical, and Yangzijiang Pharmaceutical Group are under review and approval
.

Source: NMPA official website, Mi Nei.
com database

The review data statistics are as of July 27, if there are any errors or omissions, please correct me
.